Compare BioNTech SE - ADR (BNTX) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Cenovus Energy Inc — how do they compare? BioNTech SE - ADR trades at $93.27 (market cap $23.31B), while Cenovus Energy Inc trades at $30.17 (market cap $55.00B). The key difference: Cenovus Energy Inc is far larger — about 2.4× BioNTech SE - ADR's market cap, and Cenovus Energy Inc pays a 2.09% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CVE | |
|---|---|---|
Market Cap | $23.31B | $55.00B |
Sector | Health | Energy |
52-Week High | $119.34 | $31.80 |
52-Week Low | $83.89 | $14.83 |
Enterprise Value | $6.60B | $61.08B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Cenovus Energy (CVE) trades at $29.56, up 4.64% with bullish technical momentum. The stock shows strong fundamentals with attractive valuation ratios (P/E 11.56, EV/EBITDA 5.77) and solid profitability (ROE 20.96%). Recent Q2 2026 earnings matched estimates with record oil sands production driving operational strength. Analyst consensus leans positive with 40.7% buy ratings despite mixed quarterly performance.
CVE presents value opportunity with robust cash flow generation and production growth, though faces commodity price volatility risks. Wall Street sentiment remains cautiously optimistic with institutional accumulation supporting upside potential. Key risks include oil price dependency and refining margin pressures that could impact earnings stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
